Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

The Trial, which is expected to begin in December 2024, will evaluate the immunogenicity and safety of the YSJA rabies vaccine across two distinct four-dose immunization schedules to determine ...

Premature infants (defined as infants born before 37 weeks of gestational age) in stable clinical condition, regardless of birth weight, should be immunized with age-appropriate doses of vaccine at ...

Merck (NS:PROR) & Co., Inc. (NYSE:MRK), a global leader in the biopharmaceutical industry, continues to navigate a complex landscape of opportunities and challenges as it solidifies its position in ...

Vaccination is a critical tool to help protect the health of people in Canada. By working with communities and strengthening our public health system, we can optimize the impact of vaccination so that ...

In June this year, the FDA approved Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.

The new recommendation could grow a lucrative market for vaccines that’s long been dominated by Pfizer’s Prevnar franchise, but now includes additional and emerging entrants designed to provide ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 14–1 in favor of expanding the agency’s guidance for pneumococcal vaccines—such as Merck’s Capvaxive and Pfizer’s Prevnar 20—to ...